Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
GnRH agonist
Leuprolide
Lupron · Leup
GnRH agonist whose kidney risk is indirect — metabolic syndrome, bone loss and cardiovascular strain.
MildGnRH agonist (androgen deprivation) · approved 1985
Prostate cancerOther hormone-responsive tumors
Signature kidney injury
Hypertension
No characteristic direct nephrotoxicity. Androgen-deprivation therapy is associated with metabolic syndrome, insulin resistance, dyslipidemia and increased cardiovascular disease, which raise long-term renovascular risk; a large matched cohort (n≈19,079) found CKD to be an independent risk factor for ADT-associated fracture, and preclinical models show GnRH-agonist-induced metabolic syndrome and atherosclerosis.
Source: Hopmans et al., Urol Oncol 2014 (preclinical) / Alibhai, J Urol 2010 (cohort)
Mechanism of kidney injury
Profound testosterone suppression promotes visceral adiposity, dyslipidemia, insulin resistance and hypertension (a metabolic-syndrome phenotype), accelerating atherosclerosis and chronic renovascular and cardiovascular injury rather than acute tubular damage. The renal effect is therefore indirect and longitudinal — driven by the cardiometabolic consequences of hypogonadism, not by a tubular toxin. The initial testosterone flare is a tumor/symptom concern, not a renal one.
Clinical presentation
Weight gain, new dyslipidemia, rising blood pressure and impaired glucose tolerance over months to years; accelerated bone loss. No specific acute renal lesion; any GFR change is mediated through cardiometabolic disease.
Onset
Months to years (metabolic/cardiovascular and skeletal).
Reversibility
Variable
Anticancer mechanism
GnRH (LHRH) agonist that after an initial gonadotropin surge downregulates and desensitizes pituitary GnRH receptors, suppressing LH/FSH and gonadal sex-steroid production (medical castration). Used for prostate cancer and other hormone-responsive conditions.
Management
Manage hypertension, dyslipidemia and hyperglycemia per guideline targets; multidisciplinary cardiovascular risk reduction and bone protection. No drug-specific renal therapy.
Risk factors
- Pre-existing metabolic syndrome or diabetes
- Established cardiovascular disease
- Prolonged/continuous androgen deprivation
- Older age
- Baseline CKD
Prevention
- Cardiovascular and metabolic risk-factor screening and management
- Blood-pressure, lipid and glucose monitoring
- Bone-health assessment (DXA, calcium/vitamin D)
- Lifestyle modification; consider intermittent ADT where appropriate
Note · Kidney risk is a downstream consequence of the metabolic/cardiovascular effects of androgen deprivation, not a direct nephrotoxicity. GnRH antagonists may carry a somewhat smaller cardiometabolic signal than agonists in some data.
Clinical depth
Renal dose adjustment
No renal dose adjustment; leuprolide is a peptide cleared by peptidase/tissue metabolism and is dosed by depot interval, not renal function.
Dialyzability & ESKD dosing
Peptide depot formulation; not relevant to dialyzability and no ESKD dose change needed. The clinical focus in ESKD is cardiometabolic and bone management.
Differential diagnosis
Distinguish ADT-driven metabolic-syndrome hypertension/CKD from primary renovascular or diabetic kidney disease; an acute creatinine change is not expected from the drug and warrants an alternative explanation.
Monitoring
- Blood pressure, fasting lipids and glucose/HbA1c periodically
- Weight/waist circumference
- Bone density (DXA) and vitamin D
- Cardiovascular risk reassessment
Key trials & series
- Alibhai J Urol 2010 matched ADT cohort (CKD an independent fracture risk factor)
- Hopmans Urol Oncol 2014 preclinical metabolic-syndrome/atherosclerosis model
Clinical pearls
- Leuprolide injures the kidney only indirectly — through years of ADT-induced metabolic syndrome and atherosclerosis.
- There is no acute renal lesion and no renal dose adjustment; the management is cardiometabolic and skeletal.
- Screen for and treat hypertension, dyslipidemia, hyperglycemia and bone loss proactively in men on long-term ADT.
- CKD itself amplifies ADT-related fracture risk — pay extra attention to bone health in CKD patients.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
HypertensionElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of gnrh agonists.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- QT, hypertension, fluid retention
Musculoskeletal
Myalgia, myositis, rhabdomyolysis, ONJ
- Bone loss, fatigue, hot flashes
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Transaminitis (abiraterone)
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkGnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model.Hopmans SN et al. · Urol Oncol 2014 · PMID 25242517Shows GnRH agonist (leuprolide) induces metabolic syndrome and atherosclerosis — the basis for indirect renovascular risk.PMIDFracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.Alibhai SMH et al. · J Urol 2010 · PMID 20643458Large matched cohort identifying chronic kidney disease as an independent risk factor for ADT-associated fracture.PMIDAttenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats.Bhandarkar NS et al. · Mar Drugs 2018 · PMID 29794984Leuprolide worsens metabolic syndrome and cardiovascular function in a testosterone-deprivation model.PMIDThe Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.Iacovelli R et al. · Clin Genitourin Cancer 2017 · PMID 29339044Context for the cardiovascular/renovascular burden of hormonal prostate-cancer therapy that compounds ADT metabolic risk.PMIDCardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.El-Taji O et al. · JAMA Oncol 2024 · PMID 38842801Quantifies cardiovascular events with androgen-pathway therapy, supporting the indirect renovascular risk of androgen deprivation.PMIDConventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis 2021 · PMID 35190107Onconephrology reference for indirect/cardiometabolic contributions to chronic kidney disease.
Related agents
Other agents sharing the same signature kidney injury.